Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05783830
Other study ID # D2000C0-001
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date January 13, 2020
Est. completion date April 18, 2020

Study information

Verified date March 2023
Source AlzeCure Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 0, open-label, non-controlled, single-centre study designed to evaluate the pharmacokinetics (PK) and safety and tolerability of a single, bolus intravenous (iv) injection of a microdose of ACD856 in healthy subjects.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date April 18, 2020
Est. primary completion date April 18, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Healthy males aged >18 and <65 years. - Signed and dated informed consent prior to any study-mandated procedure - Willing and able to comply with study requirements. - BMI >18.0 and <30.0 kg/m^2 - Male subjects must be willing to use condom or be vasectomised or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of dosing until 3 months after dosing with the IMP. - Clinically normal medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator. Exclusion Criteria: - History of any clinically significant disease or disorder which may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study. - Any planned major surgery within the duration of the study. - Clinically relevant findings in laboratory parameters, ECG or vital signs at screening - History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity - Regular use of any prescribed or non-prescribed medication - Planned treatment or treatment with another investigational drug within 3 months - Current smokers or users of nicotine products. - Positive screen for drugs of abuse or alcohol at screening - History of alcohol abuse or excessive intake of alcohol - Presence or history of drug abuse - History of, or current use of, anabolic steroids. - Excessive caffeine consumption - Plasma donation within one month of screening or blood donation during the 3 months prior to screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ACD856
IV injection 100 mcg

Locations

Country Name City State
Sweden Uppsala University Hospital Uppsala

Sponsors (1)

Lead Sponsor Collaborator
AlzeCure Pharma

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under the plasma concentration vs time curve from time zero extrapolated to infinity a pharmacokinetic measure of the amount of study medication present in the blood 24 hours
Primary AUC from time zero to time of last quantifiable analyte concentration a pharmacokinetic measure of the amount of study medication present in the blood 96 hours
Primary Half-life associated with terminal slope of a semi-logarithmic concentration-time curve a pharmacokinetic measure of the time it takes for the study drug to be eliminated from the blood 24 hours
Primary Total body clearance following iv administration a pharmacokinetic measure of the time it takes for the study drug to be eliminated from the blood 24 hours
Primary Volume of distribution following iv administration a theoretical estimate of how much of the study drug that the body may contain 24 hours
Secondary Number of subjects with adverse events how many participants have reported a drug related advers event 5 days
Secondary Number of subjects with clinically significant changes in vital signs how many participants have had any clinically significant changes in vital signs 5 days
Secondary Number of subjects with clinically significant changes in 12-lead electrocardiograms (ECGs) how many participants have had study drug related changes to cardiac function 5 days
Secondary Number of subjects with clinically significant changes in haematology and clinical chemistry and/or urinalysis how many participants have had study drug related changes in laboratory test analyses 5 days
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A